BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS | MicrobiomeTrials← Back to trialsNCT06704152
BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
TERMINATEDPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2025-02-04Est. Completion: 2026-09-08
Enrollment target: 2 participants Locations- City of Hope National Medical Center, Duarte, California, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- University of Michigan, Ann Arbor, Michigan, United States
- University of Minnesota, Minneapolis, Minnesota, United States
- Washington University at St Louis, St Louis, Missouri, United States
- The Ohio State University, Columbus, Ohio, United States
Other microbiome trials you might be interested in
AML - Acute Myeloid LeukemiaAML With Mutated NPM1AML, Adult Recurrent
The goal of this clinical trial is to test BSB-2002 which is a new type of cellular therapy to treat blood cancer (AML).…
St Louis, United StatesCompleted Sep 8, 2026
Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
This phase II trial studies the possible benefits of venetoclax and ASTX727 in treating patients with acute myeloid leuk…
Houston, United States
Est. completion Oct 31, 2026